

Cover Story
Clinical
Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Twitter star Vinay Prasad retires @VinayPrasadMD
- Otis Brawley looks back on a year of great science and greater challenges
- A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”
- Dana-Farber to pay $15M to U.S. government in research fraud settlement
















